CTLA-4 blockade was shown to potentiate the production of TAA-specific antibodies as well as a CD4+ and CD8+ antigen-specific T cell response in patients with melanoma, ovarian and prostate cancer [45, 53–56]. The gene discussed is CD8A; the disease is prostate cancer.